Skip to main content

Table 2 Antibiotic susceptibility tests by pathogen and continents

From: Bacterial pathogens and resistance causing community acquired paediatric bloodstream infections in low- and middle-income countries: a systematic review and meta-analysis

 

Ampicillin

Third generation cephalosporins

Gentamicin

Amikacin

Chloramphenicol

Cotrimoxazole

Ciprofloxacin

Nalidixic acid

Clindamycin

S. aureus

Africa

37/369 (10.0)

91/129 a (70.5)

372/414 (89.9)

0/0 (−)

234/373 (62.7)

180/351 (51.3)

0/0 (−)

0/0 (−)

16/22 (72.7)

Asia

12/77 (15.6)

39/43 a (90.7)

155/186 (83.3)

63/81 (77.8)

66/85 (77.6)

63/79 (79.7)

0/0 (0.0)

0/0 (−)

55/76 (72.4)

Total

49/446 (11.0)

130/172 a (75.6)

527/600 (87.8)

63/81 (77.8)

300/458 (65.5)

243/430 (56.5)

0/0 (−)

0/0 (−)

71/98 (72.4)

S. pneumoniae

Africa

531/569 b (93.3)

132/132 (100.0)

2/20 (10.0)

0/0 (−)

556/605 (91.9)

347/596 (58.2)

0/0 (−)

0/0 (−)

20/20 (100.0)

Asia

25/32 b (78.1)

0/0 (−)

0/0 (−)

0/0 (−)

4/4 (100.0)

1/5 (20.0)

0/0 (−)

0/0 (−)

0/0 (−)

Total

556/601 b (92.5)

132/132 (100.0)

2/20 (10.0)

0/0 (−)

560/609 (92.0)

348/601 (57.9)

0/0 (−)

0/0 (−)

20/20 (100.0)

E. coli

Africa

13/236 (5.5)

52/66 (78.8)

183/265 (69.1)

8/8 (100.0)

79/281 (28.1)

37/251 (14.7)

9/9 (100.0)

0/0 (−)

Asia

27/105 (25.7)

64/93 (68.8)

37/66 (56.1)

38/54 (70.4)

41/109 (37.6)

20/55 (36.4)

38/60 (63.3)

46/53 (86.8)

Total

40/341 (11.7)

116/159 (73.0)

220/331 (66.5)

46/62 (74.2)

120/390 (30.8)

57/306 (18.6)

47/69 (68.1)

46/53 (86.8)

Klebsiella sp.

Africa

0/20 (0.0)

0/0 (−)

16/19 (84.2)

8/8 (100.0)

7/19 (36.8)

6/18 (33.3)

0/0 (−)

0/0 (−)

Asia

30/489 (6.1)

123/477 (25.8)

93/480 (19.4)

247/471 (52.4)

100/489 (20.4)

12/18 (66.7)

183/471 (38.9)

15/18 (83.3)

Total

30/509 (5.9)

123/477 (25.8)

109/499 (21.8)

255/479 (53.2)

107/508 (21.1)

18/36 (50.0)

183/471 (38.9)

15/18 (83.3)

non-typhoidal Salmonella

Africa

196/654 (30.0)

94/94 (100.0)

488/564 (86.5)

9/10 (90.0)

316/656 (48.2)

232/646 (35.9)

7/7 (100.0)

0/0 (−)

Asia

36/44 (81.8)

39/39 (100.0)

0/0 (−)

0/0 (−)

6/7 (85.7)

39/44 (88.6)

35/36 (97.2)

7/7 (100.0)

Total

232/698 (33.2)

133/133 (100.0)

488/564 (86.5)

9/10 (90.0)

322/663 (48.6)

271/690 (39.3)

42/43 (97.7)

7/7 (100.0)

S. Typhi

Africa

Asia

333/499 (66.7)

300/323 (92.9)

139/190 (73.2)

162/190 (85.3)

332/493 (67.3)

279/332 (84.0)

210/245 (85.7)

202/274 (73.7)

Total

333/499 (66.73)

300/323 (92.9)

139/190 (73.2)

162/190 (85.3)

332/493 (67.3)

279/332 (84.0)

210/245 (85.7)

202/274 (73.7)

H. influenzae

Africa

80/157 (50.95)

0/0 (−)

22/23 (95.7)

0/0 (−)

70/147 (47.6)

204/388 (52.6)

0/0 (−)

0/0 (−)

Asia

 

Total

80/157 (50.95)

0/0 (−)

22/23 (95.7)

0/0 (−)

70/147 (47.6)

204/388 (52.6)

0/0 (−)

0/0 (−)

  1. Results are shown as: n susceptible isolates/n isolates tested (%) aIn 2 studies [32, 33], we made the assumption that oxacillin susceptible isolates were susceptible to 3rd geneneration cephalosporins, whereas susceptibility to 3rd geneneration cephalosporins was specifically tested in 2 other studies [21, 28]
  2. b S. pneumoniae isolates have been tested to penicillin